Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
08:19am, Tuesday, 21'st Jan 2025
CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
08:30am, Monday, 13'th Jan 2025
Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for epil
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
10:56am, Thursday, 09'th Jan 2025
Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.
Here's Why Momentum in Catalyst (CPRX) Should Keep going
10:01am, Thursday, 09'th Jan 2025
Catalyst (CPRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our s
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
09:20am, Thursday, 09'th Jan 2025
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
02:57pm, Wednesday, 08'th Jan 2025
Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035. The post IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
12:30pm, Wednesday, 08'th Jan 2025
As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Teva Receives a License to Market Generic FIRDAPSE Beginning in Febr
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
11:06am, Tuesday, 07'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
10:51am, Tuesday, 24'th Dec 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
10:40am, Wednesday, 18'th Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:03am, Monday, 16'th Dec 2024
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Why Is Catalyst (CPRX) Down 6.7% Since Last Earnings Report?
06:49am, Monday, 09'th Dec 2024
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
03:26pm, Monday, 02'nd Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock
11:01am, Wednesday, 27'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution
